Kebillidi is the first gene therapy to gain FDA approval for the treatment of aromatic L-amino acid decarboxylase deficiency.
Beyond the Ordinary Beyond the Obvious
Beyond the Ordinary Beyond the Obvious
Kebillidi is the first gene therapy to gain FDA approval for the treatment of aromatic L-amino acid decarboxylase deficiency.
